Navigation Links
NIH announces phase III clinical trial of creatine for Parkinson's disease

rl Kieburtz, M.D., M.P.H., of the University of Rochester in New York, and Barbara C. Tilley, Ph.D., of the Medical University of South Carolina in Charleston, and the patients will be seen by movement disorders specialists at the NET-PD sites across the United States and Canada.

PD is a degenerative disorder of the brain in which patients develop symptoms such as progressive tremor, slowness of movements, and stiffness of muscles. It affects at least one million people in the United States. Although certain drugs, such as levodopa, can reduce the symptoms of PD, there are no proven treatments that can slow the progressive deterioration in function.

Creatine is marketed as a nutritional supplement. Studies have suggested that it can improve the function of mitochondria, which produce energy inside cells. It also may act as an antioxidant that prevents damage from compounds that are harmful to cells in the brain. In a mouse model of PD, creatine is able to prevent loss of the cells that are typically affected.

"Creatine, or any compound that may slow the progression of PD, could have very important long-term benefits for people who are living with this disease," says John R. Marler, M.D., NINDS associate director for clinical trials.

The study will enroll people who have been diagnosed with PD within the past five years and who have been treated for two years or less with levodopa or other drugs that increase the levels of dopamine in the brain. Many of the symptoms of PD result from the loss of dopamine, a neurotransmitter that helps to control movement. Half of the participants will receive creatine and half will receive a placebo. Neither the participants nor their doctors will know which treatment they receive.

"We are studying a stage of the disease that usually hasn't been included in clinical studies," notes Dr. Kieburtz. The study is designed to include a broad range of people, with special efforts to
'"/>

Source:NIH/National Institute of Neurological Disorders and Stroke


Page: 1 2 3

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
4. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
5. GlycoFi announces the first production of antibodies with human glycosylation in yeast
6. NHGRI announces new sequencing targets
7. CHAVI announces international search for genes affecting HIV response
8. NHGRI announces latest sequencing targets
9. MUHC announces a transplant first in Quebec
10. St. Jude announces breakthrough in eye cancer treatment
11. Worlds largest rainforest drying experiment completes first phase
Post Your Comments:
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
(Date:3/17/2015)... , March 17, 2015 Emotient, the ... software, today announced general availability of Emotient ... for the analysis of facial expressions. The system ... media content, products and services. It delivers audience ... and sentiment - as derived from facial evidence ...
(Date:3/16/2015)... Germany , March 16, 2015 ... Identification Systems GmbH will present groundbreaking innovations in ... Hanover, Germany .      ... DERMALOG,s latest biometric innovation is well at the ... next generation e-gate made in Germany ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... the proteins that allow specific brain cells to "change channels," ... cell. The findings, described in the March 24 issue of ... using it to protect cells that die in Lou Gehrig's ... comes into the living room, these brain cells are able ...
... identifies a critical inhibitory step that is a ... balance between neutrophil production and destruction. The research, ... that the process for disposal of dying neutrophils ... understanding of the processes that control neutrophil turnover ...
... of the causes of child deaths to date, published ... that worldwide more than 70% of the 10.6 million ... causes: pneumonia (19%), diarrhoea (18%), malaria (8%), neonatal sepsis ... birth (8%). , Robert Black (Johns Hopkins Bloomberg School ...
Cached Biology News:Some Brain Cells 'Change Channels' To Fine-tune The Message 2Some Brain Cells 'Change Channels' To Fine-tune The Message 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2New Estimates For The Causes Of Child Deaths Worldwide 2
(Date:3/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... certain matters, including the appointment of auditors, its annual ... 2015 (the "Meeting") was adjourned, as previously disclosed on ... a.m. ( Toronto time). The date ... previous disclosed. The Meeting will reconvene at the offices ...
(Date:3/26/2015)... 26, 2015  BioNano Genomics, Inc., the leader in ... as chief commercial officer. Salyer has more than ... teams in life sciences. At BioNano, Salyer will oversee ... genome-mapping platform to assemble a comprehensive view of complex ... date, 32 institutions located in the United ...
(Date:3/26/2015)... 26, 2015 Neogen Corporation (NASDAQ: NEOG ... third quarter of fiscal 2015, which ended Feb. 28, ... year,s $6,575,000. Earnings per share in the current quarter ... year-to-date net income increased 17% over prior year to ... $0.56 per share, for the same period a year ...
(Date:3/26/2015)... 2015 ReliantHeart, Inc., an innovative supplier ... supplier of precision transit-time flow measurement solutions, are collaborating ... the efficiency of the HeartAssist5® Left Ventricular ... experience greater mobility and peace of mind. , ... board, will draw 1/6th of the power required by ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Genetics, Flurizan Will Earn a 23%,Patient Share in the United States, According ... ... Resources, WALTHAM, Mass., Feb. 5 Decision Resources, one of the,world,s ... a drug,s effect on delaying the progression,from mild cognitive impairment to Alzheimer,s ...
... Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company focused ... the chronic inflammation,underlying cardiovascular and neurological disease, today ... a Company Overview at BIO,CEO & Investor Conference ... 11:00,a.m. (ET) on Tuesday, February 12, 2008. The ...
... SOUTH SAN FRANCISCO, Calif., Feb. 5 Anesiva,Inc. (Nasdaq: ... fourth quarter,and year ended 2007 after the markets close ... teleconference at 4:30 p.m. EDT that day. Members,of Anesiva,s ... and full year 2007 as well as provide an ...
Cached Biology Technology:Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation 2
... The CHEMICON Re-Blot Plus Western Blot ... removal of antibodies from Western blots that ... iodine or other isotopes. It is not ... 4-chloronapthol, etc.), as it is not possible ...
... as a 5x solution. Designed to ... proteins without destroying antigenic binding capacity. ... signals from blots. Not recommended for ... a 5X solution sufficient to strip ...
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
Biology Products: